0.60Open0.55Pre Close448 Volume760 Open Interest23.50Strike Price7.78KTurnover1812.67%IV7.30%PremiumNov 22, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type-0.0446Delta0.0876Gamma1266.50Leverage Ratio-23.9188Theta0.0000Rho-56.53Eff Leverage0.0001Vega
Hims & Hers Health Stock Discussion
up nearly 4% in overnight trading following Trump’s nomination of Marty Makary as Head of the FDA.
Dr. Makary currently serves as the Chief Medical Officer of Sesame, a telehealth platform that also offers compounded versions of GLP-1s.
Pre market is 26.35 +3.6%. Strong start to potentially revisit 30 this week.
Overview
Hims & Hers Health (HIMS) has been a standout performer in 2024, delivering an impressive 194.94% year-to-date return. The company has demonstrated significant growth momentum, driven by strong fundamentals and increasing investor confidence. The recent technical breakout highlights continued upside potential for the stock.
Current Price Analysis
• Current Price (Nov 22, 2024): $25.33
• Daily Change: +$1.18 (+4.89%)
• Post-Mar...
$CrowdStrike (CRWD.US)$ | Stifel analyst Adam Borg maintains CrowdStrike Holdings with a Buy and raises the price target from $300 to $375.
$Alibaba (BABA.US)$ | Barclays analyst Jiong Shao maintains Alibaba with a buy rating, and adjusts the target price from $137 to $130.
$Robinhood (HOOD.US)$ | Bernstein analyst Gautam Chhugani maintain...
Hims & Hers Launches Meal Replacement Bars And Shakes To Enhance Personalized Weight Loss Plans, Offering Comprehensive Nutrition Support For Customers Starting At $110/Month
funds rotating out of tech?
to the moon
No comment yet